{"id":"lansoprazole-amoxicillin-clarithromycin","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Taste disturbance"},{"rate":"3-8","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment hostile to H. pylori. Amoxicillin and clarithromycin are antibiotics that work synergistically—amoxicillin disrupts bacterial cell wall synthesis while clarithromycin inhibits bacterial protein synthesis. Together, these three agents achieve high eradication rates of H. pylori infection.","oneSentence":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid while simultaneously disrupting bacterial cell wall and protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:12.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in patients with peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT05926804","phase":"NA","title":"A \"Screen and Treat\" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile","status":"RECRUITING","sponsor":"Miguel O'Ryan Gallardo","startDate":"2022-08-02","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT06964334","phase":"PHASE3","title":"The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-06-01","conditions":"Helicobacter Pylori Infection","enrollment":70},{"nctId":"NCT03130452","phase":"PHASE4","title":"Helicobacter Pylori Eradication Study","status":"COMPLETED","sponsor":"Inje University","startDate":"2016-12-17","conditions":"Helicobacter Pylori Infection","enrollment":423},{"nctId":"NCT02387203","phase":"PHASE2","title":"Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mercy Medical Center","startDate":"2015-01","conditions":"Pseudomyxoma Peritonei, Appendiceal Neoplasms","enrollment":80},{"nctId":"NCT01678027","phase":"PHASE3","title":"Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2004-11","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Family Members","enrollment":1838},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT05933031","phase":"PHASE2","title":"Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-27","conditions":"Helicobacter Pylori Infection","enrollment":381},{"nctId":"NCT05861687","phase":"PHASE2, PHASE3","title":"Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children","status":"COMPLETED","sponsor":"Finni Kollins","startDate":"2021-08-01","conditions":"Helicobacter Pylori Infection","enrollment":51},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":"Helicobacter Pylori Infection","enrollment":1046},{"nctId":"NCT05301725","phase":"","title":"Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy Against Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori; Eradication Rate","enrollment":670},{"nctId":"NCT05259007","phase":"PHASE4","title":"Effect of Propolis on Patients Infected With H. Pylori","status":"UNKNOWN","sponsor":"Fatma Zehra Arvas","startDate":"2022-02-22","conditions":"Helicobacter Pylori Infection","enrollment":96},{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT03317223","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2017-10-17","conditions":"Helicobacter Pylori Infection","enrollment":350},{"nctId":"NCT03050307","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-17","conditions":"Gastric Ulcer","enrollment":234},{"nctId":"NCT02646332","phase":"NA","title":"Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2015-12","conditions":"Helicobacter Pylori Infection","enrollment":248},{"nctId":"NCT03716622","phase":"PHASE4","title":"A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2018-07-31","conditions":"Helicobacter Pylori","enrollment":350},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533},{"nctId":"NCT03498456","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-06-28","conditions":"Helicobacter Pylori Infection","enrollment":284},{"nctId":"NCT02557932","phase":"PHASE3","title":"Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-09","conditions":"Helicobacter Pylori Infection, Family History of Stomach Cancer","enrollment":352},{"nctId":"NCT04101708","phase":"PHASE4","title":"A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-09-20","conditions":"Helicobacter Pylori","enrollment":100},{"nctId":"NCT03487562","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-04-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT03837990","phase":"","title":"One Sequencing Find All for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-05-01","conditions":"Helicobacter Pylori Infection, Resistant Infection","enrollment":60},{"nctId":"NCT03829150","phase":"NA","title":"Dexlansoprazole MR-Based Concomitant Quadruple Therapy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-03-01","conditions":"Helicobacter Pylori Infection","enrollment":202},{"nctId":"NCT03516669","phase":"PHASE4","title":"Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2018-05-07","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT02892409","phase":"PHASE1","title":"TAK-438 Bismuth Drug Interaction Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-05","conditions":"Helicobacter Pylori","enrollment":30},{"nctId":"NCT03654781","phase":"PHASE1","title":"Impact of Periodontal Treatment on Gastric Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2008-04-21","conditions":"Helicobacter Pylori Infection","enrollment":98},{"nctId":"NCT03571230","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":400},{"nctId":"NCT03124420","phase":"PHASE4","title":"Intraluminal Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2017-04-28","conditions":"Helicobacter Pylori Infection","enrollment":100},{"nctId":"NCT01906879","phase":"PHASE4","title":"Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-06","conditions":"Helicobacter Pylori Infection","enrollment":1620},{"nctId":"NCT02711176","phase":"PHASE4","title":"Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Zahra Vahdat Shariatpanahi","startDate":"2016-09","conditions":"Helicobacter Infection","enrollment":212},{"nctId":"NCT02633930","phase":"PHASE4","title":"Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2015-12","conditions":"Gastritis, Peptic Ulcer, Dyspepsia","enrollment":566},{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230},{"nctId":"NCT02388581","phase":"PHASE2","title":"First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL","status":"UNKNOWN","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12","conditions":"Gastric Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT02682446","phase":"","title":"The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2007-01","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT02541786","phase":"PHASE4","title":"Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2015-01","conditions":"Helicobacter Pylori Infection","enrollment":177},{"nctId":"NCT01481844","phase":"PHASE3","title":"Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2011-11","conditions":"Optimization of Second Line Treatment Protocol for H Pylori Eradication","enrollment":101},{"nctId":"NCT01418300","phase":"PHASE4","title":"Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial","status":"COMPLETED","sponsor":"Jun-Won Chung","startDate":"2010-08","conditions":"Helicobacter Infected Patients","enrollment":159},{"nctId":"NCT01888237","phase":"PHASE4","title":"High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2013-05","conditions":"Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders","enrollment":118},{"nctId":"NCT02175901","phase":"PHASE4","title":"Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2014-07","conditions":"Dyspepsia, Peptic Ulcer","enrollment":215},{"nctId":"NCT02249546","phase":"PHASE4","title":"Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-09","conditions":"Helicobacter Pylori Infection","enrollment":654},{"nctId":"NCT00461084","phase":"","title":"Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-04","conditions":"Lymphoma","enrollment":36},{"nctId":"NCT01505127","phase":"PHASE3","title":"Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-01","conditions":"H. Pylori Infection","enrollment":650},{"nctId":"NCT01607918","phase":"PHASE4","title":"Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rates of the Two Regimens","enrollment":1300},{"nctId":"NCT01922505","phase":"","title":"Eradication Rates of Helicobacter Pylori and Its Affecting Factors","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2003-01","conditions":"Helicobacter Infections","enrollment":2500},{"nctId":"NCT00467571","phase":"PHASE4","title":"Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2006-03","conditions":"Chronic Idiopathic Thrombocytopenic Purpura, Helicobacter Pylori Infection","enrollment":26},{"nctId":"NCT01042184","phase":"PHASE4","title":"Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-12","conditions":"H. Pylori Infection","enrollment":900},{"nctId":"NCT01061437","phase":"PHASE3","title":"S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-06","conditions":"Helicobacter Pylori Infection","enrollment":1859},{"nctId":"NCT00816140","phase":"PHASE4","title":"Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-06","conditions":"Helicobacter Infections","enrollment":432},{"nctId":"NCT01255332","phase":"","title":"Helicobacter Pylori Immune Thrombocytopenic Purpura","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2010-09","conditions":"Immune Thrombocytopenic Purpura","enrollment":26},{"nctId":"NCT00990405","phase":"PHASE4","title":"Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia","status":"UNKNOWN","sponsor":"Korean College of Helicobacter and Upper Gastrointestinal Research","startDate":"2009-10","conditions":"Functional Dyspepsia, Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT00983034","phase":"NA","title":"The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2006-03","conditions":"Nephrotic Syndrome, Glomerulonephritis, Membranous Nephropathy","enrollment":70},{"nctId":"NCT00926809","phase":"PHASE4","title":"H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection","status":"UNKNOWN","sponsor":"Korean College of Helicobacter and Upper Gastrointestinal Research","startDate":"2008-09","conditions":"Ulcer","enrollment":232},{"nctId":"NCT00149084","phase":"PHASE3","title":"Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori","status":"UNKNOWN","sponsor":"Hamamatsu University","startDate":"2003-04","conditions":"Helicobacter Infections, Gastritis, Gastric Ulcer","enrollment":296},{"nctId":"NCT00281047","phase":"PHASE2, PHASE3","title":"The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy","status":"UNKNOWN","sponsor":"Hamamatsu University","startDate":"2006-01","conditions":"Helicobacter Pylori","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20230816","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20220304","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20240611","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20230718","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20220414","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20220304","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20161007","type":"ORIG","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20240612","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"}],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lansoprazole triple therapy (LAC)"],"phase":"marketed","status":"active","brandName":"Lansoprazole/Amoxicillin/Clarithromycin","genericName":"Lansoprazole/Amoxicillin/Clarithromycin","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid while simultaneously disrupting bacterial cell wall and protein synthesis. Used for Helicobacter pylori eradication in patients with peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}